drugset / Trial / NCT03342027

Smoking Cessation Interventions for People Living With HIV in Nairobi, Kenya

NCT03342027

Phase 3 Completed 300 enrolled University of Maryland, Baltimore
RandomizedFactorialDouble-blindTreatment

Summary

The proposed study will use a factorial design to evaluate the most promising and accessible behavioral and pharmacologic treatments aimed at achieving maximal efficacy for smoking cessation among people living with HIV who smoke. The study will randomize 300 participants people living with HIV , who smoke and who are receiving care in HIV clinics affiliated with the Center for International Health, Education, and Biosecurity in Nairobi, Kenya to one of the following 4 conditions: (1) bupropion + Positively Smoke Free (an 8 session tailored behavioral intervention for people living with HIV smokers); (2) bupropion + Standard of Care (brief advice to quit); (3) Placebo + Positively Smoke Free; and (4) Placebo + Standard of Care.

Timeline

Start
2020-08-01
Primary completion
2023-07-25
Completion
2023-07-25

Drugs

EvaluationDrugModalityDoseRoute
Subject Bupropion Small molecule